Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A worker checks the production of chloroquine in China. Photo: Feature China/Barcroft Media via Getty Images

The Trump administration is taking a very public interest in chloroquine, an old, cheap anti-malarial drug, as a potential coronavirus treatment, although it's way too soon to put much stock in its effectiveness.

What they're saying: The Food and Drug Administration is investigating whether the drug can reduce the duration of patients' symptoms in mild to moderate cases, or to reduce "viral shedding," which helps prevent disease spread.

As I reported earlier this week, pharma company Bayer is donating a large quantity of its version of the drug, Resochin, to the U.S. government. Bayer confirmed the donation of 3 million tablets yesterday.

  • "Currently not approved for use in the United States, Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug's use in the U.S.," the company said in a statement.

Yes, but: Awareness of the drug's potential has bolstered demand. Chloroquine and its variant hydroxychloroquine have gone into shortage, Business Insider reports.

  • The drug is also used to treat arthritis or lupus, and the shortages could threaten the health of patients who rely on it.

My thought bubble: Remember that this is an unproven treatment; there's absolutely no guarantee that it will help treat coronavirus.

Go deeper

Updated 19 mins ago - Sports

The Olympic events to watch today

Katie Ledecky. Photo: Al Bello/Getty Images

5 events to watch today...
  • Baseball: USA plays Israel in the opening round at 6 a.m. ET on nbcolympics.com (Watch the replay at 10:30 a.m. ET on NBC Sports).
  • Women’s soccer: USA takes on the Netherlands in the quarterfinals at 7 a.m. ET on NBC Sports (watch the replay at 6 p.m. ET on NBC Sports).
  • 🏊 🚴 🏃‍♀️ Team triathlon: The mixed team relay Triathlon makes its Olympic debut at 6:30 p.m. ET on USA Network.
  • 🏊‍♀️ Swimming finals: Watch Katie Ledecky swim the women’s 800m freestyle final and Caeleb Dressel go for his third gold at this year’s Games in the men’s 50m freestyle. Plus live action from the mixed 4x100m medley relay. Coverage starts at 9:30 p.m. ET on NBC.
  • 🏃‍♀️ Track and field: Athletes compete in prelims and round 1 of several events, including the women’s 400m hurdles and men’s 100m.
Ina Fried, author of Login
28 mins ago - Technology
Column / Signal Boost

Japan tests teleporting games and "remote cheering"

NTT is using augmented reality holograms to transport an Olympic badminton match to the National Museum of Emerging Science and Innovation. Photo: NTT

Japanese telecom giant NTT is using the Olympics to show off a new generation of technologies that can transport the sporting experience to wherever fans are, instead of making them come to games.

Why it matters: Technology like this would have solved tons of problems this year, when no spectators are allowed at the actual Olympic venues. Unfortunately, it's all available only in demo form right now.

56 mins ago - Health

America's new approach to masks is even more scattershot than before

Illustration: Brendan Lynch/Axios

In grocery stores and pizza joints, main streets and downtowns across the country, pandemic precautions range wildly — from nonexistent to 2020 deja vu.

The big picture: As COVID-19 cases surge, especially in states with low vaccination rates, the country is once again in the throes of a fraught cultural and political debate over face masks.